TORONTO and HAIFA, Israel, May 30, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“ NurExone ” or the “ Company ”) is pleased to announce that Professor Nahshon Knoller M.D., senior clinical advisor to the Company, will be presenting at the prestigious annual meeting of the American Spinal Injury Association (“ ASIA ”), where he will discuss the Company’s plans for future clinical... Read More

TORONTO and HAIFA, Israel, May 27, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“ NurExone ” or the “ Company ”), a preclinical-stage biotechnology company pioneering exosome-based therapies for central nervous system injuries, is pleased to announce its financial results for the first quarter ended March 31, 2025, and provides a corporate update on its recent activities and upcoming... Read More

TORONTO and HAIFA, Israel, May 08, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“ NurExone ” or the “ Company ”), a preclinical-stage biotechnology company pioneering exosome-based therapies for central nervous system injuries, is pleased to announce that its preclinical data on optic nerve regeneration study was presented today at the Annual Meeting of the Association for Research... Read More

TORONTO and HAIFA, Israel, May 02, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“ NurExone ” or the “ Company ”), a preclinical-stage biotechnology company pioneering exosome-based therapies for central nervous system injuries, is deepening its engagement with the European financial and healthcare communities through participation in three upcoming events. This increased activity... Read More

TORONTO and HAIFA, Israel, April 24, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) a preclinical-stage biotechnology company pioneering exosome-based therapies for central nervous system injuries is presenting new data at the 2025 International Society for Extracellular Vesicles (ISEV) Annual Meeting being held in Vienna April 24-27. The ISEV presentation... Read More

TORONTO and HAIFA, Israel, April 22, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“ NurExone ” or the “ Company ”), a preclinical-stage biotechnology company pioneering regenerative exosomes-based therapies for central nervous system injuries, is pleased to announce the appointment of Jacob Licht as Chief Executive Officer of Exo-Top Inc. (“ Exo-Top ”), a wholly owned subsidiary of... Read More

TORONTO and HAIFA, Israel, April 10, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“ NurExone ” or the “ Company ”) is pleased to provide a business update and reported financial results for the fourth quarter and financial year ended December 31, 2024. The Company’s audited consolidated financial statements for the fiscal years ended December 31, 2024 and 2023 and accompanying... Read More

TORONTO and HAIFA, Israel, April 04, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX, OTCQB: NRXBF, Germany: J90) (“ NurExone ” or the “ Company ”) is pleased to announce that, subject to TSX Venture Exchange (“ TSXV ”) approval, it has closed a non-brokered private placement of 3,543,238 units (“ Units ”) at a price of C$0.65 per Unit for aggregate gross proceeds of C$2,303,105 (the “ Offering ”). The Company... Read More

TORONTO and HAIFA, Israel, March 14, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“ NurExone ” or the “ Company ”) is pleased to announce that it has successfully completed an important preclinical study towards its Investigational New Drug (“ IND ”) submission. The new study, which... Read More

TORONTO and HAIFA, Israel, Feb. 27, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) is pleased to announce that it has been selected to present at MIXiii 2025, Israel’s premier Health Tech conference, organized by the Israeli Advanced Technology Industries. NurExone will participate in a special session, Innovation in Ophthalmology , showcasing cutting-edge... Read More

TORONTO and HAIFA, Israel, Feb. 19, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“ NurExone ” or the “ Company ”) is proud to announce its inclusion in the 2025 TSX Venture 50™ , a prestigious annual ranking of the top-performing companies on the TSX Venture Exchange (“ TSXV ”). NurExone is honored to be the only biotech company, and one of three life sciences companies, to receive... Read More

TORONTO and HAIFA, Israel, Feb. 14, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (Germany: J90) (“ NurExone ” or the “ Company ”) is excited to announce that it will be presenting at the International Society for Cell & Gene Therapy (ISCT) 2025 Annual Meeting (“ ISCT 2025 ”), a major global cell and gene therapy translation conference, taking place from May 7-10, 2025 in New Orleans, Louisiana,... Read More

TORONTO and HAIFA, Israel, Feb. 05, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (Germany: J90) (“ NurExone ” or the “ Company ”) is pleased to announce the formation of a U.S.-based subsidiary, Exo-Top Inc. (“ Exo-Top ”), that is expected to advance good manufacturing practice (“ GMP ”), fully characterized exosome production. The establishment of Exo-Top is a key step towards an independent... Read More

TORONTO and HAIFA, Israel, Jan. 21, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (“ NurExone ” or the “ Company ”), a developer of exosome-based therapies for regenerative medicine, is pleased to announce that, subject to TSX Venture Exchange (“ TSXV ”) approval, it has closed a non-brokered private placement of 856,996 units (“ Units ”) at a price of C$0.56 per Unit for... Read More

TORONTO and HAIFA, Israel, Jan. 08, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (" NurExone " or the " Company "), a developer of exosome-based therapies for regenerative medicine, is pleased to announce that it has acquired a master cell bank from a U.S. manufacturer for an undisclosed amount (the “ Acquisition ”). The Acquisition marks a major step in ensuring a stable and... Read More

TORONTO and HAIFA, Israel, Dec. 06, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (" NurExone " or the " Company "), a biopharmaceutical company developing exosome-based regenerative therapies, has announced significant findings from an expanded preclinical study of the potential... Read More

TORONTO and HAIFA, Israel, Nov. 27, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (Germany: J90) (the “ Company ” or “ NurExone ”), a pioneering biopharmaceutical company developing regenerative medicine therapies, is pleased to announce its financial and operational results for the three and nine months ended September 30, 2024, the highlights of which are included in this news release. The... Read More

TORONTO and HAIFA, Israel, Nov. 13, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (Germany: J90) (" NurExone " or the " Company "), a biopharmaceutical company developing exosome-based regenerative therapies, is pleased to announce that the European Medicines Agency (the “ EMA ”) has granted Orphan Medicinal Product Designation for the Company’s ExoPTEN therapy, marking a significant step towards... Read More

TORONTO and HAIFA, Israel, Nov. 01, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “ Company ” or “ NurExone ”), a biopharmaceutical company developing exosome-based therapies for the multi-billion dollar regenerative medicine i market, is pleased to announce, further to its press release dated September 26, 2024 (the “ September 26 Release ”), the closing of the final... Read More

TORONTO and HAIFA, Israel, Oct. 23, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc . (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “ Company ” or “ NurExone ”), a biopharmaceutical company developing exosome-based therapies for the multi-billion dollar regenerative medicine i market, announced its invitation to present at two conferences in exosome science this November in the United States. These invitations underscore... Read More

TORONTO and HAIFA, Israel, Sept. 26, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “ Company ” or “ NurExone ”), a biopharmaceutical company developing exosome-based therapies for the multi-billion dollar regenerative medicine i market, is pleased to announce a non-brokered private placement of up to 3,636,363 units (“ Units ”) at a price of $0.55 per Unit for aggregate... Read More

TORONTO and HAIFA, Israel, Sept. 12, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “ Company ” or “ NurExone ”), a biopharmaceutical company developing exosome-based therapies for the multi-billion dollar regenerative medicine i market , is pleased to announce its participation in a series of prestigious conferences this October. These events will showcase the Company’s... Read More

TORONTO and HAIFA, Israel, Sept. 06, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “ Company ” or “ NurExone ”) is pleased to announce compelling new findings that highlight the therapeutic potential of ExoPTEN for patients with spinal cord injuries. In a recent preclinical... Read More

TORONTO and HAIFA, Israel, Aug. 28, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company developing regenerative medicine therapies, is pleased to announce its financial and operational results for the three and six months ended June 30, 2024, the highlights of which are included in this news release. The Company’s... Read More

TORONTO and HAIFA, Israel, Aug. 23, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “ Company ” or “ NurExone ”) is pleased to announce that its Chief Executive Officer, Dr. Lior Shaltiel, has been invited to speak at the upcoming Bioprocess International Conference being held from September 23 – 26 in Boston, MA. NurExone’s participation in this event highlights the Company’s... Read More

Company demonstrates reliable production from multiple biological sources These manufacturing advancements provide NurExone flexibility in optimizing its exosome production method, ensuring consistency while maintaining efficiency TORONTO and HAIFA, Israel, Aug. 15, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX),... Read More

TORONTO and HAIFA, Israel, Aug. 09, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (Germany: J90) (the “ Company ” or “ NurExone ”) is pleased to announce new data for its ExoPTEN nanodrug, marking a significant step towards commercial-grade manufacturing. Building on the announcement of a new Good... Read More

TORONTO and HAIFA, Israel, Aug. 01, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “ Company ” or “ NurExone ”), a pioneering biopharmaceutical company, is thrilled to announce an important milestone in its regenerative medicine efforts. The Company has successfully transferred... Read More

TORONTO and HAIFA, Israel, July 29, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “ Company ” or “ NurExone ”), a pioneering biopharmaceutical company developing regenerative medicine therapies, is pleased to announce that the Israel Patent Office recently issued a Notice of Allowance for an ExoPTEN patent, covering innovative Extracellular Vesicles (EVs) comprising a... Read More

TORONTO and HAIFA, Israel, July 17, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company, is pleased to announce the preliminary results from a small-scale controlled study exploring the use of its flagship nanodrug,... Read More

TORONTO and HAIFA, Israel, July 05, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “ Company ” or “ NurExone ”), a pioneering biopharmaceutical company, is pleased to announce two significant updates aimed at advancing our mission and improving stakeholder engagement. Dr. Lior Shaltiel, Chief Executive Officer of NurExone, will be presenting at the Emerging Growth Conference... Read More

TORONTO and HAIFA, Israel, June 28, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “ Company ” or “ NurExone ”), a pioneering biopharmaceutical company, is pleased to announce a pre-clinical study to explore the potential of NurExone’s exosome-based therapies in regenerating... Read More

TORONTO and HAIFA, Israel, June 21, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “ Company ” or “ NurExone ”), a pioneering biopharmaceutical company, welcomes Dr. Yona Geffen, as a consultant, to support the Company’s preclinical and clinical activities. Dr. Geffen, who currently serves as Vice President of Research and Development at Gamida Cell Ltd. (“ Gamida Cel l ”),... Read More

TORONTO and HAIFA, Israel, June 11, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “ Company ” or “ NurExone ”), a pioneering biopharmaceutical company developing regenerative medicine therapies, is pleased to announce that the Japan Patent Office recently issued a Notice of Allowance for an ExoPTEN patent, covering innovative Extracellular Vesicles (EVs) comprising a... Read More

TORONTO and HAIFA, Israel, June 04, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “ Company ” or “ NurExone ”), a pioneering biopharmaceutical company developing regenerative medicine therapies, is pleased to announce the voting results from its annual general and special meeting of shareholders (“ Shareholders ”) held on Monday, June 3, 2024 via live webcast (the “ Meeting... Read More

TORONTO and HAIFA, Israel, May 29, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc . (TSXV: NRX) (OTCQB: NRXBF) (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company developing regenerative medicine therapies, is pleased to announce its financial and operational results for the three months ended March 31, 2024, the highlights of which are included in this news release. The Company’s full set of... Read More

TORONTO and HAIFA, Israel, May 17, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “ Company ” or “ NurExone ”), a pioneering biopharmaceutical company, proudly welcomes Dr. Ram Petter, Ph.D., MBA, as a consultant, to assist in driving the Company’s strategic collaborations. With a distinguished background in the pharmaceutical industry, including significant tenure and... Read More

TORONTO and HAIFA, Israel, April 25, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “ Company ” or “ NurExone ”), a pioneering biopharmaceutical company is pleased to announce that its common shares are now quoted for trading on the OTCQB ® Venture Market (the " OTCQB ") under the symbol NRXBF. The OTCQB listing enhances visibility and facilitates trading by US institutional and retail... Read More

TORONTO and HAIFA, Israel, April 19, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company, is pleased to announce that Dr. Lior Shaltiel, CEO and Director at NurExone, was invited to present on "Revolutionizing Spinal Cord Injury Treatment: Harnessing the Potential of Exosomes for Advanced Therapy in Comprehensive Approach" at the... Read More

TORONTO and HAIFA, Israel, April 02, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company, developing regenerative medicine therapies, today provided a business update and reported financial results for the fourth quarter and financial year ended December 31, 2023. Fourth Quarter Highlights and Significant Milestones On October 26,... Read More

TORONTO and HAIFA, Israel, March 27, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “Company” or “NurExone”), is pleased to announce that, the Company completed a combined exercise and expiration of 12,682,340 common share purchase warrants issued pursuant to a private placement of units that closed on June 15, 2022. Following the Acceleration Event, as defined and further detailed in its... Read More

TORONTO and HAIFA, Israel, March 22, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “ Company ” or “ NurExone ”), a pioneering biopharmaceutical company, developing regenerative medicine therapies, is proud to announce a strategic service agreement with Vivox Ltd. (“Vivox”), a leading provider of animal testing and services in Israel to biotech and pharmaceutical companies. This large-scale... Read More

TORONTO and HAIFA, Israel, March 15, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “ Company ” or “ NurExone ”), a pioneering biopharmaceutical company, developing regenerative medicine therapies, announces today its intention to broaden its market reach through a recently filed application for listing on the OTCQB® Venture Market (the "OTCQB") in the United States. Listing on the OTCQB is... Read More

TORONTO and HAIFA, Israel, March 08, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “ Company ” or “ NurExone ”), a pioneering biopharmaceutical company, finalized today a lease and constructing agreement for nearly 200 square meters of laboratories and office space on the campus of the prestigious Israel Institute of Technology (“ Technion ”). The lease period extends until December 31,... Read More

TORONTO and HAIFA, Israel, March 01, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company, is pleased to announce that Dr. Ina Sarel, the Head of CMC, Quality and Regulatory Affairs at NurExone, will be leading a workshop at the upcoming Exosome Characterization & Analytical Development Summit. Dr. Sarel will be sharing with her... Read More

TORONTO and HAIFA, Israel, Feb. 20, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company, proudly underscores its expanding Intellectual Property (IP) portfolio, which will serve as the foundation for its strategic goal of licensing the innovative ExoTherapy platform to interested biotech companies. NurExone’s Intellectual property... Read More

TORONTO and HAIFA, Israel, Feb. 14, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “Company” or “NurExone”), a biopharmaceutical company, announced today the commencement of efforts to license its proprietary ExoTherapy platform for creating nanodrugs by loading therapeutic molecular cargo into exosomes. Exosomes, which have a natural affinity for inflamed tissues, deliver loaded therapeutic... Read More

TORONTO and HAIFA, Israel, Feb. 02, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V), known as "NurExone," is pleased to announce the initiation of the Orphan Drug Designation process with the European Medicines Agency (EMA) for its groundbreaking ExoPTEN product, currently in development for patients with acute spinal cord injury. This strategic move follows the recent grant of Orphan Drug... Read More

TORONTO and HAIFA, Israel, Jan. 17, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the “ Company ” or “ NurExone ”), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spinal cord injuries, is pleased to share several updates. The collaborative agreement between NurExone and Inteligex Inc. (“ Inteligex ”), announced in October 2023, to... Read More

TORONTO and HAIFA, Israel , Jan. 05, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the “ Company ” or “ NurExone ”), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spinal cord injuries, is pleased to announce that it has closed a non-brokered private placement (the “ Private Placement ”). An aggregate of 7,091,993 units of the Company... Read More

TORONTO and HAIFA, Israel, Nov. 29, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the “Company” or “NurExone”) has recently unveiled laboratory tests of its secondary two proprietary sequences, representing a significant advancement in the treatment of spinal cord injuries. The... Read More

TORONTO and HAIFA, Israel, Nov. 24, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the “Company” or “NurExone”), a pioneering biotechnology company, released a corporate update and reported financial results for the quarter ended September 30, 2023. “I am pleased to report that we have reached a new pivotal point for our proprietary ExoPTEN drug, primarily in advancing our United States Food... Read More

TORONTO and HAIFA, Israel, Oct. 30, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the “Company” or “NurExone”), a pioneering biotechnology company, is thrilled to announce that the U.S. Food and Drug Administration (FDA) has granted Orphan-Drug Designation (ODD) for its ExoPTEN therapy, recognizing the potential of this groundbreaking regenerative therapy for acute spinal cord injury, a... Read More

TORONTO and HAIFA, Israel, Oct. 19, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the “Company” or “NurExone”), a biopharmaceutical company developing biologically-guided exosome therapy (“ExoTherapy”) for patients with traumatic spinal cord injuries, is honored to welcome Professor Teodoro Forcht Dagi, a renowned neurosurgeon, life science venture capitalist and professor at the Mayo Clinic... Read More

TORONTO and HAIFA, Israel, Oct. 11, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the “ Company ” or “ NurExone ”), a biopharmaceutical company developing biologically-guided exosome therapy (“ ExoTherapy ”) for patients with acute spinal cord injuries (“ SCI ”), is thrilled to announce that the Company has been awarded a 1M New Israeli Shekels (NIS) (~CAD$350K) grant by the Israel... Read More

TORONTO and HAIFA, Israel, Oct. 05, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the “Company” or “NurExone”), a biopharmaceutical company developing biologically-guided exosome therapy (“ExoTherapy”) for patients with traumatic spinal cord injuries, is excited to announce excited to announce that Dr. Lior Shaltiel, CEO of NurExone Biologic, will be presenting advances in exosome-based... Read More

TORONTO and HAIFA, Israel, Sept. 28, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the “ Company ” or “ NurExone ”), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spinal cord injuries, is pleased to announce that it has entered into an investor relations agreement (the “ Agreement ”) with Dr. Reuter Investor Relations GmbH (“ Dr.... Read More

The FDA’s response indicated that the planned toxicity study strategy is acceptable under FDA guidelines and large-scale animal studies will not be required. The completed Pre-IND meeting with the FDA is expected to expedite NurExone’s regulatory process to initiate Phase 1/2 human clinical studies in 2025. TORONTO and HAIFA, Israel, Sept. 13, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V)... Read More

TORONTO and HAIFA, Israel, Sept. 06, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the “ Company ” or “ NurExone ”), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spinal cord injuries, is pleased to announce that it has closed the second and final tranche (the “ Second Tranche ”) of its previously announced non-brokered private... Read More

Completed the first tranche of a non-brokered private placement offering of units for gross proceeds of approximately CAD$1.3 million to extend cash runway into 2024 Strengthened the Board of Directors through the appointment of Dr. Gadi Riesenfeld, Former President of Pharmos Corporation (a publicly traded biotech company listed on NASDAQ) Positive imaging results from an internal preclinical study of its investigational... Read More

TORONTO and TEL AVIV, Israel, Aug. 09, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (“ NurExone ” or the “ Company ”) announces that it intends to complete a non-brokered private placement (the “ Private Placement ”) of a minimum of 2,727,272 units (“ Units ”) and a maximum of 5,090,909 Units at a price of CAD$0.275 per Unit for minimum gross proceeds of $750,000 and maximum gross proceeds... Read More

TORONTO and TEL AVIV, Israel, July 20, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (“NurExone” or the “Company”) is pleased to announce significant advancements in extracellular vesicles (EVs) functionality. Leveraging its proprietary and patented 3D-Flow production, the Company has achieved... Read More

Toronto, Ontario and Tel Aviv, Israel--(Newsfile Corp. - July 7, 2023) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (" NurExone " or the " Company ") is pleased to announce that, effective July 6, 2023, Dr. Gadi Riesenfeld has been appointed to the board of directors of the Company replacing Mr. Ron Mayron, who resigned for personal reasons. Dr. Riesenfeld has served on the board of directors and as president of... Read More

TORONTO and TEL AVIV, Israel, June 22, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. ("NurExone" or the "Company") (TSXV: NRX) (FSE: J90) (NRX.V), is pleased to report positive imaging results from an internal preclinical study of its investigational drug ExoPTEN. The image analysis and measurements confirmed successful... Read More

MUNICH, Germany and TEL AVIV, Israel, June 01, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc . (the "Company" or "NurExone") (TSXV: NRX) (FSE: J90), a biopharmaceutical company developing biologically-guided exosome therapy ("ExoTherapy") for patients with traumatic spinal cord injuries, is pleased to announce a pioneering collaboration with the German company, Particle Metrix, a leading provider of particle analysis... Read More

TORONTO and TEL AVIV, Israel, May 24, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (the "Company" or "NurExone") (TSXV: NRX) (FSE: J90) (NRX.V), a biopharmaceutical company developing biologically-guided exosome therapy ("ExoTherapy") for patients with traumatic spinal cord injuries, has released its financial results for the quarter ended March 31, 2023. “The Company is successfully achieving key milestones for our... Read More

TORONTO and TEL AVIV, Israel, May 16, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (the " Company " or " NurExone ") (TSXV: NRX) (FSE: J90) (NRX.V), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spinal cord injuries, announces that the Company has received an issue notification from the United States Patent and Trademark Office (“USPTO”) for U.S. Patent NO.... Read More

Toronto, Ontario and Tel Aviv, Israel--(Newsfile Corp. - May 12, 2023) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy ("ExoTherapy") for patients with traumatic spinal cord injuries, announced that it has engaged Litchfield Hills Research, LLC ("Litchfield") to perform investor relations services and activities,... Read More

Toronto, Ontario and Tel Aviv, Israel--(Newsfile Corp. - May 8, 2023) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the " Company " or " NurExone "), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spinal cord injuries, announces that it has granted an aggregate of 1,145,520 incentive stock options (" Options ") and 1,275,000 restricted share units (" RSUs ")... Read More

TORONTO and TEL AVIV, Israel, March 30, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (the "Company" or "NurExone") (TSXV: NRX) (FSE: J90) (NRX.V), a biopharmaceutical company developing biologically-guided exosome therapy ("ExoTherapy") for patients with traumatic spinal cord injuries, has released its financial results for 2022, the first since it became public last June. NurExone's research and development investment... Read More

TORONTO and TEL AVIV, Israel, March 20, 2023 (GLOBE NEWSWIRE) -- Toronto and Tel Aviv, March 20, 2023 - Biopharmaceutical firm NurExone Biologic Inc . (TSXV: NRX) (FSE: J90) (NRX.V) (“NurExone” or the “Company”), disclosed today additional results from an internal preclinical study of its investigational drug ExoPTEN demonstrating effective treatment of 75% of paralyzed rats suffering from spinal cord injuries. The Company’s... Read More

TORONTO and HAIFA, Israel, Feb. 17, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V), a biopharmaceutical company developing biologically-guided exosome therapy ("ExoTherapy"), for patients with traumatic spinal cord injuries, is pleased to announce the interim results of an internal, preclinical study of its ExoPTEN drug. ExoPTEN is being developed by NurExone as a minimally invasive drug,... Read More

TORONTO and TEL AVIV, Israel, Feb. 13, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V), a Toronto-listed biopharmaceutical company, is developing ExoPTEN, a proprietary platform for producing and loading exosomes with pharmaceutical cargo targeting spinal cord injuries (SCI) intranasally. NurExone has established itself as a unique company by possessing both a product in development, ExoPTEN,... Read More

The patent covers NurExone's ExoPTEN drug compositions and treatment methods for Central Nervous System disease Haifa, Israel and Calgary, Alberta--(Newsfile Corp. - January 12, 2023) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy ("ExoTherapy") for patients with traumatic spinal cord injuries, has received a notice of... Read More

Calgary, Alberta--(Newsfile Corp. - December 15, 2022) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) ("we", "our", the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy ("ExoTherapy") for patients with traumatic spinal cord injuries, is pleased to provide the following... Read More

Calgary, Alberta--(Newsfile Corp. - December 7, 2022) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (formerly, EnerSpar Corp. or "EnerSpar") (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spine injuries, is announcing today that it completed its securities for debt settlement on December 6, 2022, previously announced by the Company on... Read More

Company's analysis indicates the successful achievement of its proprietary loading technology for producing exosome-based therapies Calgary, Alberta--(Newsfile Corp. - December 1, 2022) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided... Read More

NurExone Biologic Inc. (TSXV: NRX) (formerly, EnerSpar Corp. or "EnerSpar") (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spine injuries, is announcing today that it has agreed to settle debts in the amount of CAD$46,523.69 with the issuance of 122,430 common shares of the Company at a deemed price of CAD$0.38 per share. These debts were... Read More

NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy ("ExoTherapy") for patients with traumatic spinal cord injuries, released a corporate update and reported financial results for the quarter ended September 30, 2022. "Obtaining U.S. FDA approval for our drug platform remains a priority for NurExone and we intend to continue... Read More